<DOC>
	<DOCNO>NCT02314923</DOCNO>
	<brief_summary>Ebola virus infect killed people , mostly Africa . In 2014 , Ebola virus affect several thousand people . There approved effective way treat prevent Ebola . Researchers try develop vaccine . This study anti-Ebola vaccine BPSC-1001 see safe see affect people 's immune system .</brief_summary>
	<brief_title>Placebo Controlled , Dose Response , Safety Immunogenicity Study Vesicular Stomatitis Virus ( VSV ) Ebola Vaccine Healthy Adults ( V920-004 )</brief_title>
	<detailed_description>Between 1994 present , many Ebola virus ( EBOV ) outbreaks affect mostly central Africa . However , 2014 West African outbreak significantly exceed previous outbreak geographic range , number individual affect disruption typical activity civil society . This Phase 1 safety tolerability study evaluate novel vaccine Ebola use live replicate vesicular stomatitis virus ( VSV ) replace gene encode G envelope glycoprotein gene encode envelope glycoprotein Zaire strain Ebola ( VSVΔG-ZEBOV also know BPSC-1001 ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject 1 . Healthy adult male nonpregnant , nonlactating adult female , age 18 60 ( inclusive ) time screen 2 . Have provide write informed consent prior screen procedure 3 . Free clinically significant health problem , determine pertinent medical history , physical examination clinical judgment investigator . 4 . Available , able , willing participate study visit procedure . 5 . Males females willing practice abstinence sexual intercourse opposite sex , willing use effective method contraception , least 30 day prior vaccination study end . 6 . Be willing minimize blood body fluid exposure others 7 day vaccination : 1 . Using effective barrier prophylaxis , latex condom , penetrative sexual intercourse 2 . Avoiding share needle , razor , toothbrush 3 . Avoiding openmouth kiss 7 . Resides geographic area clinical study site 1 year vaccination without risk deployment outside U.S. Subject Subjects meeting follow criterion exclude study : 1 . History prior infection filovirus prior participation filovirus vaccine trial 2 . History prior infection VSV receipt VSV vectored vaccine 3 . Has involve care capacity patient Ebola virus infection within previous 21 day 4 . Is healthcare worker direct contact patient ( nurse , physician , dentist , emergency medical technician , dental hygienist ) 5 . Has household contact ( HHC ) immunodeficient , immunosuppressive medication , human immunodeficiency virus ( HIV ) positive , pregnant , unstable medical condition 6 . Has HHC , childcare worker direct contact child , 5 year age younger 7 . Direct handson job prepare food food industry 8 . History employment industry involve contact ruminant animal , veterinary science , potential exposure VSV 9 . History employment activity involve potential contact filoviruses 10 . History severe local systemic reaction vaccination history severe allergic reaction 11 . Known allergy component BPSC1001 vaccine product 12 . Receipt investigational product 30 day prior randomization ongoing participation another clinical trial 13 . Receipt license nonlive vaccine within 14 day plan study immunization ( 30 day live vaccine ) 14 . Ability observe possible local reaction eligible injection site ( deltoid region ) , opinion investigator , unacceptably obscure due physical condition permanent body art 15 . Acute chronic , clinically significant psychiatric , hematologic , pulmonary , cardiovascular , hepatic renal functional abnormality determine investigator base medical history , physical examination , and/or laboratory screen test . This would include know hemoglobinopathy coagulation abnormality . 16 . Any baseline laboratory screen test opinion investigator , consider clinically significant 17 . Any serologic evidence hepatitis B C infection 18 . Any confirmed suspected immunosuppressive immunodeficient condition , include HIV1 , HIV2 infection , cytotoxic therapy previous 5 year , and/or diabetes 19 . Any chronic active neurologic disorder , include migraine , seizure , epilepsy , exclude single febrile seizure child 20 . Have know history GuillainBarré Syndrome 21 . Have active malignancy history metastatic hematologic malignancy 22 . Suspected known alcohol and/or illicit drug abuse within past 5 year 23 . Moderate severe illness and/or fever &gt; 100.4°F within 1 week prior vaccination ( subject reschedule ) 24 . Pregnant lactate female , female intend become pregnant study period 25 . Administration IgGs and/or blood product within 120 day precede study entry plan administration study period 26 . History blood donation within 60 day enrollment plan donate within study period 27 . Administration chronic ( defined 14 day ) immunosuppressant immune modify drug within 6 month study entry 1 . For corticosteroid , include prednisone , equivalent , great equal 0.5 mg/kg/day 2 . Intranasal , topical , intraarticular steroid allow 28 . Unwilling allow storage use blood future vaccine research 28 . Research staff immediate family research staff directly involve clinical study . 29 . Unwilling undergo diagnostic evaluation joint sign symptom , may include arthrocentesis clinically indicate base presence effusion procedure acceptable subject time ( Cohort 2 ) 30 . Unwilling undergo diagnostic evaluation skin rash , include punch biopsy clinically indicated procedure acceptable subject time ( Cohort 2 ) 31 . Research staff immediate family research staff directly involve clinical study 32 . Any significant finding opinion investigator would increase risk individual adverse outcome participate study 33 . Elective surgery hospitalization plan period study participation 34 . Subject travel area World Health Organization declare Ebola outbreak zone 35 . History chronic inflammatory disease ( e.g. , rheumatoid arthritis , psoriatic arthritis , reactive arthritis , ankylose spondylitis , systemic lupus erythematosus , psoriasis , Crohn 's disease , ulcerative colitis , gout ) , symptomatic osteoarthritis , autoimmune autoinflammatory disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>